Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2018
Jun. 30, 2017
Current assets:    
Cash $ 3,398 $ 8,088
Accounts receivable - trade 181 175
Work in process 0 26
Prepaid expenses and other current assets 407 283
Total Current Assets 3,986 8,572
Fixed assets, net of accumulated depreciation 25,335 25,589
Intangible assets, net of accumulated amortization 1,687 1,823
Security deposit 26 26
Total Assets 31,034 36,010
Current liabilities:    
Accounts payable (related party of $101 and $87 as of March 31, 2018 and June 30, 2017, respectively) 939 749
Accrued expenses (related party of $478 and $650 as of March 31, 2018 and June 30, 2017, respectively) 746 924
Capital lease obligation - current portion 194 183
Deferred revenue 68 157
Total Current Liabilities 1,947 2,013
Capital lease obligation - net of current portion 24,935 25,082
Total Liabilities 26,882 27,095
Commitments and Contingencies
iBio, Inc. Stockholders' Equity:    
Preferred stock - $0.001 par value; 1,000,000 shares authorized; 1 share issued and outstanding as of both March 31, 2018 and June 30, 2017 0 0
Common stock - $0.001 par value; 275,000,000 and 175,000,000 shares authorized as of March 31, 2018 and June 30, 2017, respectively,115,918,510 and 89,118,510 shares issued and outstanding as of March 31, 2018 and June 30, 2017, respectively 116 89
Additional paid-in capital 87,877 80,977
Accumulated other comprehensive loss (29) (29)
Accumulated deficit (83,810) (72,123)
Total iBio, Inc. Stockholders' Equity 4,154 8,914
Noncontrolling interest (2) 1
Total Equity 4,152 8,915
Total Liabilities and Equity $ 31,034 $ 36,010